Prelude Capital Management’s Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 CNDA.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-74,966
Closed -$7.82K 1435
2023
Q3
$7.82K Buy
+74,966
New +$5.06K ﹤0.01% 1083

Other funds holding CNDA.WS

Prelude Capital Management's CNDA.WS Position: Q4 2023 in Review

Prelude Capital Management sold out of Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 (CNDA.WS) in Q4 2023, closing a stake of 74,966 shares — an estimated $7.82K sold.

Prelude Capital Management first reported a position in CNDA.WS in Q3 2023 and held it in 1 quarter. The position peaked at $7.82K in Q3 2023. 27 funds tracked by Wall St. Rank hold CNDA.WS as of Q4 2023.

  • Prelude Capital Management reported no remaining Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 74,966 Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 shares in Q4 2023, an estimated $7.82K.
  • Prelude Capital Management first reported a position in Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 in Q3 2023 and held it in 1 quarter.
  • Prelude Capital Management's Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position peaked at $7.82K in Q3 2023.
  • 27 funds tracked by Wall St. Rank held Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.